Clinical trial NCT05306340: A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
Official title: A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Patients With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Lead sponsor: Genentech, Inc.
Sponsor class: INDUSTRY
First posted: 2022-04-01
Enrollment: 320
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the physician's choice of endocrine therapy plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have had previous treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) and endocrine therapy, either in the locally advanced/metastatic or the adjuvant setting.


Eligibility criteria: Inclusion Criteria:

1. Locally advanced unresectable or metastatic adenocarcinoma of the breast, not amenable to treatment with curative intent
2. Documented estrogen receptor-positive (ER+) tumor and HER2-negative tumor, assessed locally
3. Ability to provide a blood sample for circulating-tumor deoxyribonucleic acid (ctDNA) Estrogen Receptor 1 (ESR1) mutation status determination by central testing
4. Prior endocrine therapy (ET) in combination with cyclin-dependent kinase 4/6 inhibitors in either setting as follows:

   * Metastatic setting: Disease progression after ≥6 months on ET plus CDK4/6 inhibitor in the locally advanced or metastatic setting. If ET plus CDK4/6 inhibitor is not the most recent therapy, then patient must also have had disease progression after ≥4 months on most recent ET
   * Adjuvant Setting: Relapse either while taking or within 12 months of exposure to combination adjuvant ET and CDK4/6 inhibitor. Patients must have taken at least 12 months of adjuvant ET, 6 months of which was in combination with a CDK4/6 inhibitor.
5. Measurable disease as defined per RECIST v.1.1 or evaluable bone metastases. Patients with evaluable bone disease in the absence of measurable disease outside of the bone must have at least one predominantly lytic bone lesion confirmed by computed tomography (CT) or magnetic resonance imaging (MRI) which can be followed
6. Eastern Cooperative Oncology Group Performance Status 0-1
7. For women who are premenopausal or perimenopausal and for men: treatment with approved luteinizing hormone-releasing hormone (LHRH) agonist therapy for the duration of study treatment

Exclusion Criteria:

1. Prior treatment with another oral selective estrogen receptor degrader (SERD), proteolysis targeting chimera (PROTAC), complete estrogen receptor antagonist (CERAN), novel oral selective estrogen receptor modulator (SERM), or everolimus in any setting. Prior fulvestrant is allowed if treatment was terminated at least 28 days prior to randomization. Prior treatment with tamoxifen is allowed.
2. Progression on more than 2 prior lines of systemic endocrine therapy in the locally advanced unresectable or metastatic breast cancer setting
3. Prior chemotherapy for locally advanced unresectable or metastatic disease
4. Treatment with strong Cytochrome P450 3A4 (CYP3A4) inhibitors or inducers within 14 days or 5 drug elimination half-lives (whichever is longer) prior to randomization
5. Treatment with any investigational therapy within 28 days prior to initiation of study treatment
6. Major surgery, chemotherapy, radiotherapy, or other anti-cancer therapy within 14 days prior to randomization
7. History of any other malignancy other than breast cancer within 5 years prior to screening, except for appropriately treated carcinoma in situ of the cervix, nonmelanoma skin carcinoma, papillary thyroid cancer treated with surgery, Stage I endometrial cancer, or other non-breast cancers at very low risk of recurrence
8. Advanced, symptomatic, visceral spread that is at risk of life-threatening complications in the short term
9. Known active uncontrolled or symptomatic central nervous system (CNS) metastases, carcinomatous meningitis, or leptomeningeal disease
10. Active cardiac disease or history of cardiac dysfunction
11. Known clinically significant history of liver disease consistent with Child-Pugh Class B or C including active viral or other hepatitis virus, current alcohol abuse, or cirrhosis
12. Active inflammatory bowel disease, chronic diarrhea, short bowel syndrome, or major upper gastrointestinal (GI) surgery including gastric resection
13. Interstitial lung disease or severe dyspnea at rest or requiring oxygen therapy
14. Serious infection requiring oral or intravenous (IV) antibiotics, or other clinically significant infection, within 14 days prior to randomization
15. Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study
16. Known allergy or hypersensitivity to any of the study drugs or any of their excipients
17. For premenopausal or perimenopausal women and for men: known hypersensitivity to LHRH agonists
18. Pregnant or breastfeeding

Primary outcomes:
measure: Progression-Free Survival, as Determined by the Investigator According to RECIST v1.1, in the ESR1m Subpopulation and ITT Population
timeFrame: From randomization until the first occurrence of disease progression or death from any cause, whichever occurs first (up to 42 months)
Secondary outcomes:
measure: Overall Survival, in the ESR1m Subpopulation and ITT Population
timeFrame: From randomization until death from any cause (up to 42 months)
measure: Objective Response Rate (ORR), as Determined by the Investigator According to RECIST v1.1, in the ESR1m Subpopulation and ITT Population
timeFrame: From randomization until progressive disease or death (up to 42 months)
measure: Duration of Response (DOR), as Determined by the Investigator According to RECIST v1.1, in the ESR1m Subpopulation and ITT Population
timeFrame: From the first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to 42 months)
measure: Clinical Benefit Rate (CBR), as Determined by the Investigator According to RECIST v1.1, in the ESR1m Subpopulation and ITT Population
timeFrame: From Baseline until progressive disease or death (up to 42 months)
measure: Time to Confirmed Deterioration in Pain Severity, as Determined Using the Brief Pain Inventory Short-Form (BPI-SF) Worst Pain Item Score, in the ESR1m Subpopulation and ITT Population
timeFrame: From randomization until 90 days after treatment discontinuation (up to 42 months)
measure: Time to Confirmed Deterioration in Pain Presence and Interference, as Determined Using the EORTC QLQ-C30 Questionnaire Linearly Transformed Pain Scale Score, in the ESR1m Subpopulation and ITT Population
timeFrame: From randomization until 90 days after treatment discontinuation (up to 42 months)
measure: Time to Confirmed Deterioration in Physical Functioning (PF), as Determined Using the EORTC QLQ-C30 Questionnaire Linearly Transformed PF Scale Score, in the ESR1m Subpopulation and ITT Population
timeFrame: From randomization until 90 days after treatment discontinuation (up to 42 months)
measure: Time to Confirmed Deterioration in Role Functioning (RF), as Determined Using the EORTC QLQ-C30 Questionnaire Linearly Transformed RF Scale Score, in the ESR1m Subpopulation and ITT Population
timeFrame: From randomization until 90 days after treatment discontinuation (up to 42 months)
measure: Time to Confirmed Deterioration in Health-Related Quality of Life (HRQoL), as Determined Using the EORTC QLQ-C30 Questionnaire Linearly Transformed Global Health Status (GHS)/QoL Scale Score, in the ESR1m Subpopulation and ITT Population
timeFrame: From randomization until 90 days after treatment discontinuation (up to 42 months)
measure: Number of Participants with at Least One Adverse Event, with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, version 5 (NCI CTCAE v5.0)
timeFrame: From Baseline until 30 days after the final dose of study treatment (up to 42 months)
measure: Number of Participants with Vital Sign Abnormalities Over the Course of the Study
timeFrame: From Baseline until 30 days after the final dose of study treatment (up to 42 months)
measure: Number of Participants with Clinical Laboratory Test Abnormalities for Hematology Parameters Over the Course of the Study
timeFrame: From Baseline until 30 days after the final dose of study treatment (up to 42 months)
measure: Number of Participants with Clinical Laboratory Test Abnormalities for Biochemistry Parameters Over the Course of the Study
timeFrame: From Baseline until 30 days after the final dose of study treatment (up to 42 months)
measure: Plasma Concentration of Giredestrant at Specified Timepoints
timeFrame: Predose and 3 hours postdose on Days 1 and 15 of Cycle 1, and predose on Day 1 of Cycles 2 and 3 (1 cycle is 28 days)
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: Alabama Oncology - Bruno Cancer Center
state: Alabama
city: Anchorage
country: United States
facility: Alaska Oncology and Hematology
state: Alaska
city: Phoenix
country: United States
facility: The Dignity Health Cancer Institute
state: Arizona
city: Tucson
country: United States
facility: Arizona Oncology Associates, PC-CASA
state: Arizona
city: Hot Springs
country: United States
facility: Genesis Cancer Center
state: Arkansas
city: Little Rock
country: United States
facility: University of Arkansas for Medical Sciences
state: Arkansas
city: Anaheim
country: United States
facility: Pacific Cancer Medical Center
state: California
city: Berkeley
country: United States
facility: Alta Bates Summit Medical Center
state: California
city: Beverly Hills
country: United States
facility: Beverly Hills Cancer Center
state: California
city: Cerritos
country: United States
facility: TOI Clinical Research
state: California
city: Costa Mesa
country: United States
facility: Newport Beach UC Irvine Medical Center
state: California
city: Fresno
country: United States
facility: Women's Cancer Care
state: California
city: La Jolla
country: United States
facility: Scripps Health
state: California
city: Los Angeles
country: United States
facility: Los Angeles Hematology Oncology Medical Group
state: California
city: Orange
country: United States
facility: University of California, Irvine Medical Center
state: California
city: Redlands
country: United States
facility: Emad Ibrahim, Md, Inc
state: California
city: West Covina
country: United States
facility: Brian LeBerthon, Med Corp
state: California
city: New Haven
country: United States
facility: Yale Cancer Center
state: Connecticut
city: Norwich
country: United States
facility: Eastern CT Hematology and Oncology Associates
state: Connecticut
city: Brooksville
country: United States
facility: ASCLEPES Research Centers - Brooksville
state: Florida
city: Fort Lauderdale
country: United States
facility: Broward Health Medical Center (BHMC) (Broward General Medical Center (BGMC))
state: Florida
city: Miami Beach
country: United States
facility: Mount Sinai Medical Center
state: Florida
city: Orlando
country: United States
facility: Orlando Health Cancer Institute
state: Florida
city: Rockledge
country: United States
facility: Cancer Care Centers of Brevard
state: Florida
city: Tampa
country: United States
facility: Tampa General Hospital Cancer Institute
state: Florida
city: West Palm Beach
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Marietta
country: United States
facility: Northwest Georgia Oncology Centers PC - Marietta
state: Georgia
city: Savannah
country: United States
facility: Summit Cancer Care PC
state: Georgia
city: Meridian
country: United States
facility: St Luke?s Cancer Institute
state: Idaho
city: Chicago
country: United States
facility: Northwestern University
state: Illinois
city: Evergreen Park
country: United States
facility: OSF Little Company of Mary Hospital
state: Illinois
city: Joliet
country: United States
facility: Duly Health and Care
state: Illinois
city: Springfield
country: United States
facility: Springfield Clinic
state: Illinois
city: Indianapolis
country: United States
facility: Indiana University Melvin and Bren Simon Cancer Center
state: Indiana
city: Des Moines
country: United States
facility: Mission Cancer + Blood - IMMC
state: Iowa
city: Westwood
country: United States
facility: University of Kansas Cancer Center
state: Kansas
city: Pikeville
country: United States
facility: Pikeville Medical Center
state: Kentucky
city: Baton Rouge
country: United States
facility: Our Lady of the Lake Physicians Group
state: Louisiana
city: Baton Rouge
country: United States
facility: Woman's Hospital
state: Louisiana
city: Covington
country: United States
facility: Pontchartrain Cancer Center
state: Louisiana
city: Brewer
country: United States
facility: Northern Light Cancer Center/Oncology Research
state: Maine
city: Scarborough
country: United States
facility: New England Cancer Specialists
state: Maine
city: Annapolis
country: United States
facility: Anne Arundel Health System Research Institute
state: Maryland
city: Baltimore
country: United States
facility: University of Maryland Greenebaum Cancer Center
state: Maryland
city: Baltimore
country: United States
facility: Mercy Medical Center
state: Maryland
city: Ocean Pines
country: United States
facility: TidalHealth Peninsula Regional; Richard A. Henson Research
state: Maryland
city: Boston
country: United States
facility: Dana Farber Cancer Institute
state: Massachusetts
city: Foxboro
country: United States
facility: Dana Farber/Harvard Cancer Center (Foxborough)
state: Massachusetts
city: Milford
country: United States
facility: Dana Farber/Harvard Cancer Center (Milford)
state: Massachusetts
city: Weymouth
country: United States
facility: Dana Farber/Harvard Cancer Center (Weymouth)
state: Massachusetts
city: Saint Louis Park
country: United States
facility: Metro-Minnesota Community Oncology Research Consortium
state: Minnesota
city: Grand Island
country: United States
facility: Oncology Hematology West PC
state: Nebraska
city: Omaha
country: United States
facility: Nebraska Cancer Specialists
state: Nebraska
city: Reno
country: United States
facility: Renown Regional Medical Center
state: Nevada
city: Basking Ridge
country: United States
facility: Memorial Sloan Kettering - Basking Ridge
state: New Jersey
city: Florham Park
country: United States
facility: Summit Medical Group
state: New Jersey
city: Middletown
country: United States
facility: Memorial Sloan Kettering - Monmouth
state: New Jersey
city: Montvale
country: United States
facility: Memorial Sloan-Kettering Cancer Center
state: New Jersey
city: Farmington
country: United States
facility: San Juan Oncology Associates
state: New Mexico
city: Commack
country: United States
facility: Memorial Sloan Kettering
state: New York
city: Harrison
country: United States
facility: Memorial Sloan Kettering Cancer Center at Westchester
state: New York
city: Long Island City
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
city: New York
country: United States
facility: The Blavatnik Family ? Chelsea Medical Center at Mount Sinai
state: New York
city: New York
country: United States
facility: Icahn School of Medicine at Mount Sinai
state: New York
city: New York
country: United States
facility: Icahn School of Medicine at Mount Sinai
state: New York
city: New York
country: United States
facility: Memorial Sloan-Kettering Cancer Center
state: New York
city: Stony Brook
country: United States
facility: Stony Brook University Medical Center
state: New York
city: Uniondale
country: United States
facility: Memorial Sloan Kettering Cancer Center at Nassau
state: New York
city: Columbus
country: United States
facility: SCRI Mark H. Zangmeister Center
state: Ohio
city: Oklahoma City
country: United States
facility: University of Oklahoma Health Sciences Center
state: Oklahoma
city: Tulsa
country: United States
facility: Oklahoma Cancer Specialists and Research Institute
state: Oklahoma
city: Bend
country: United States
facility: St Charles Medical Center Bend
state: Oregon
city: Philadelphia
country: United States
facility: Abramson Cancer Center
state: Pennsylvania
city: Pittsburgh
country: United States
facility: UPMC Hillman Cancer Center - Magee-Women?s Hospital
state: Pennsylvania
city: West Chester
country: United States
facility: Abramson Cancer Center Chester County Hospital
state: Pennsylvania
city: West Reading
country: United States
facility: McGlinn Cancer Institute at Reading Hospital
state: Pennsylvania
city: Sioux Falls
country: United States
facility: Avera Cancer Institute
state: South Dakota
city: Germantown
country: United States
facility: West Cancer Center
state: Tennessee
city: Knoxville
country: United States
facility: Thompson Cancer Survival Center
state: Tennessee
city: Beaumont
country: United States
facility: Texas Oncology P.A - Beaumont
state: Texas
city: Bedford
country: United States
facility: Texas Oncology
state: Texas
city: Dallas
country: United States
facility: Texas Oncology - Baylor Charles A. Sammons Cancer Center
state: Texas
city: Denton
country: United States
facility: Texas Oncology-Denton South
state: Texas
city: El Paso
country: United States
facility: Texas Oncology, P.A. - El Paso
state: Texas
city: Houston
country: United States
facility: Houston Methodist Cancer Center
state: Texas
city: Houston
country: United States
facility: Millennium Research & Clinical Development
state: Texas
city: San Antonio
country: United States
facility: USOR - Texas Oncology - San Antonio Northeast
state: Texas
city: Fairfax
country: United States
facility: Inova Fairfax Hospital
state: Virginia
city: Fairfax
country: United States
facility: Virginia Cancer Specialists
state: Virginia
city: Norfolk
country: United States
facility: Virginia Oncology Associates
state: Virginia
city: Tacoma
country: United States
facility: Northwest Medical Specialties, PLLC
state: Washington
city: Agronomía
country: Argentina
facility: Instituto de Oncología Ángel H. Roffo
state: Ciudad Autónoma De BuenosAires
city: Recoleta
country: Argentina
facility: Fundación CENIT para la Investigación en Neurociencias
state: Ciudad Autónoma De BuenosAires
city: Ciudad Autonoma Buenos Aires
country: Argentina
facility: Consultorios Médicos Dr. Doreski
city: Cordoba
country: Argentina
facility: Centro Medico Privado CEMAIC
city: Mendoza
country: Argentina
facility: Fundacion Centro Oncologico de Integracion Regional (COIR)
city: Rosario
country: Argentina
facility: Instituto Medico de la Fundacion Estudios Clinicos
city: Rosario
country: Argentina
facility: Sanatorio Parque S.A.
city: Rosario
country: Argentina
facility: Hospital Provincial del Centenario
city: Rosario
country: Argentina
facility: Instituto de Oncologia de Rosario
city: San Juan
country: Argentina
facility: Centro Polivalente de Asistencia e Investigacion Clinica - CER San Juan
city: San Nicolás
country: Argentina
facility: Organizacion Medica de Investigacion
city: Viedma
country: Argentina
facility: Centro de Investigación Clínica ? Clínica Viedma
city: Bottrop
country: Germany
facility: Marienhospital Bottrop
city: Erlangen
country: Germany
facility: Universitaetsklinikum Erlangen
city: Essen
country: Germany
facility: Kliniken Essen-Mitte
city: Heidelberg
country: Germany
facility: Universitätsklinikum Heidelberg
city: Mainz
country: Germany
facility: Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz
city: Münster
country: Germany
facility: Universitatsklinikum Munster
city: Athens
country: Greece
facility: University of Athens, Hematological Clinic,
city: Athens
country: Greece
facility: Attikon University General Hospital
city: Cholargos
country: Greece
facility: Metropolitan General Hospital
city: Heraklio
country: Greece
facility: University General Hospital of Heraklion
city: Larissa
country: Greece
facility: University General Hospital of Larissa
city: Marousi
country: Greece
facility: IASO Obstetrics Gynecology Clinic
city: Panorama
country: Greece
facility: Agios Loucas Clinic SA
city: Patras
country: Greece
facility: Olympion Clinic
city: Patras
country: Greece
facility: University General Hospital of Patras
city: Peiraias
country: Greece
facility: Metaxa Cancer Hospital of Piraeus
city: Thessaloniki
country: Greece
facility: Interbalkan Medical Center of Thessaloniki
city: Thessaloniki
country: Greece
facility: Euromedica PPDS
city: Modena
country: Italy
facility: Azienda Ospedaliero - Universitaria di Modena Policlinico
state: Emilia-Romagna
city: Roma
country: Italy
facility: Istituto Nazionale Tumori Regina Elena IRCCS
state: Lazio
city: Genova
country: Italy
facility: Ospedale Policlinico San Martino
state: Liguria
city: Milano
country: Italy
facility: Asst Grande Ospedale Metropolitano Niguarda
state: Lombardia
city: Torrette Di Ancona
country: Italy
facility: Azienda Ospedaliero Universitaria Ospedali Riuniti
state: Marche
city: Verona
country: Italy
facility: "Azienda Ospedaliera Universitaria Integrata Verona Ospedale Borgo Trento"
state: Veneto
city: Aichi
country: Japan
facility: Aichi Cancer Center
city: Aichi
country: Japan
facility: Nagoya University Hospital
city: Chiba
country: Japan
facility: Chiba Cancer Center
city: Chiba
country: Japan
facility: National Cancer Center Hospital East
city: Ehime
country: Japan
facility: Shikoku Cancer Center
city: Hiroshima
country: Japan
facility: Hiroshima City Hiroshima Citizens Hospital
city: Hiroshima
country: Japan
facility: Hiroshima University Hospital
city: Hokkaido
country: Japan
facility: Hokkaido University Hospital
city: Hyogo
country: Japan
facility: Hyogo Cancer Center
city: Ibaraki
country: Japan
facility: University of Tsukuba Hospital
city: Kanagawa
country: Japan
facility: Kanagawa Cancer Center
city: Kanagawa
country: Japan
facility: Tokai University Hospital
city: Kumamoto
country: Japan
facility: Kumamoto University Hospital
city: Kyoto
country: Japan
facility: Kyoto University Hospital
city: Niigata
country: Japan
facility: Niigata Cancer Center Hospital
city: Osaka
country: Japan
facility: National Hospital Organization Osaka National Hospital
city: Osaka
country: Japan
facility: Osaka International Cancer Institute
city: Tokyo
country: Japan
facility: Juntendo University Hospital
city: Tokyo
country: Japan
facility: The Cancer Institute Hospital of JFCR
city: Cheongju-si
country: Korea, Republic of
facility: Chungbuk National University Hospital
city: Dongnam-gu, Cheonan-si
country: Korea, Republic of
facility: Soon Chun Hyang University Cheonan Hospital
city: Goyang-si
country: Korea, Republic of
facility: National Cancer Center
city: Seongnam-si
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
city: Seoul
country: Korea, Republic of
facility: Severance Hospital Yonsei University Health System - PPDS
city: Seoul
country: Korea, Republic of
facility: Korea University Guro Hospital
city: Singapore
country: Singapore
facility: National University Hospital
city: Singapore
country: Singapore
facility: Oncocare Cancer Centre
city: Amanzimtoti
country: South Africa
facility: Rainbow Oncology Private Practice
city: Hilton
country: South Africa
facility: Hopelands Cancer Centre
city: Johannesburg
country: South Africa
facility: Medical Oncology Centre of Rosebank
city: La Coruña
country: Spain
facility: Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología
state: LA Coruna
city: Barcelona
country: Spain
facility: Hospital Dexeus
city: Barcelona
country: Spain
facility: Hospital Clinic de Barcelona
city: Cordoba
country: Spain
facility: C.H. Regional Reina Sofia - PPDS
city: Madrid
country: Spain
facility: Hospital General Universitario Gregorio Marañon
city: Madrid
country: Spain
facility: Hospital Universitario Ramón y Cajal
city: Madrid
country: Spain
facility: Hospital Clinico San Carlos
city: Madrid
country: Spain
facility: Hospital Universitario 12 de Octubre
city: Murcia
country: Spain
facility: Hospital General Universitario J.M Morales Meseguer
city: Valencia
country: Spain
facility: Hospital Clinico Universitario de Valencia
city: Chang Hua
country: Taiwan
facility: Changhua Christian Hospital
city: Kaohsiung Country
country: Taiwan
facility: Chang Gung Memorial Hospital
city: Tainan
country: Taiwan
facility: National Cheng Kung University Hospital
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
city: Taipei
country: Taiwan
facility: Koo Foundation Sun Yat-Sen Cancer Center
city: Taipei
country: Taiwan
facility: Chang Gung Memorial Hospital - Linkou Branch
city: Ankara
country: Turkey
facility: Memorial Ankara Hastanesi
city: Sakarya
country: Turkey
facility: SAKARYA University Medical Faculty
city: Dorchester
country: United Kingdom
facility: Dorset County Hospital
city: London
country: United Kingdom
facility: North Middlesex Uni Hospital
city: Manchester
country: United Kingdom
facility: The Christie NHS Foundation Trust
city: Nottingham
country: United Kingdom
facility: Nottingham City Hospital
Study officials:
affiliation: Genentech, Inc.
name: Clinical Trials
role: STUDY_DIRECTOR
References: